Leadership

  • Hiroshi Azuma, DVM

    President

    Hiroshi Azuma, DVM

    President

    Hiroshi Azuma became President of Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) in April of 2022.  He has more than 30 years of experience in the pharmaceutical sector. Many of those years were at Mitsubishi Tanabe Pharma Corporation (MTPC), where he has held senior management positions in the Research Lab, Clinical Development, Data Science, Quality Assurance and Global Development.  He also served as Head of Planning and Coordination and Data Science at MTDA.  He most recently served as Vice President & Head of the Research Coordination Department (Sohyaku Management) at MTPC.

  • Ming Ji, MD, MS

    Vice President and Head of Drug Safety

    Ming Ji, MD, MS

    Vice President and Head of Drug Safety

    For more than 18 years, Ming has worked in clinical development and drug safety for pharmaceutical companies such as Wyeth, Amgen, TAP, and AbbVie. He has strong, diverse, global safety expertise and experience, encompassing Phase I trials, complete Life Cycle Management, and leadership of multiple product safety teams. Over the past two decades, Ming has published extensively in highly respected journals.

  • Hiroyuki Yamada, PhD

    Vice President and Head of Production Technology and Supply Chain

    Hiroyuki Yamada, PhD

    Vice President and Head of Production Technology and Supply Chain

    Hiroyuki Yamada joined Mitsubishi Tanabe Pharma Development America, Inc. in April 2018 as Director of  Production Technology & Supply Chain Department from its parent company, Mitsubishi Tanabe Pharma Corporation (MTPC).  In October 2019, he went back to MTPC as Vice President and Head of the Analytical Research Department. In August 2021, he returned to MTDA as Vice President and Head of the Production Technology & Supply Chain Department, responsible for the strengthening of global CMC (Chemistry Manufacturing & Control) development and the supply chain function.  He also directs all global CMC project teams from early development stage through launch.

    Hiroyuki has more than 25 years of experience in CMC development, including 2 years at the University of Minnesota learning the advanced analytical techniques for the characterization of the pharmaceutical drugs.  More recently, he led the Production team for edaravone (Radicava®) launch in US.

  • Mauricio Vargas-Cortes, PhD

    Vice President and Head of Clinical & Technical Operations

    Mauricio Vargas-Cortes, PhD

    Vice President and Head of Clinical & Technical Operations

    A native from Colombia, Mauricio brings twenty-seven years of experience in pharmaceutical and biotech Companies in clinical research project management and operations.  Mauricio has worked in many therapeutic areas, including infectious disease, virology, immunology, oncology, inflammation, and CNS. He previously served as Vice President and Global Head of Clinical Operations & Program Management at ReViral. Prior to that he was Vice President of Program Management & Clinical Operations at Chimerix where he was also involved in a long- standing collaboration with BARDA. He has also held leadership positions at EMD Serono, Vertex, Eli Lilly and Glaxo SmithKline.  Mauricio holds a doctorate in immunology from the University of Stockholm, Sweden and has published over 20 peer reviewed articles.

  • Deborah L. Moorer

    Head of Human Resources and General Affairs

    Deborah L. Moorer

    Head of Human Resources and General Affairs

    In her role as Head of Human Resources (HR), Deborah Moorer oversees the strategic direction of all aspects of HR and is instrumental in shaping the company’s culture and employee development. She brings more than 20 years of HR experience to the role. Prior to joining Mitsubishi Tanabe Pharma Development America, Inc., she was Vice President of HR at Ipsen Biopharmaceuticals, Senior Vice President and HR Advisor at Citibank, and Vice President of HR at Alpharma.